Ann Cardiol Cardiovasc Med | Volume 4, Issue 1 | Research Article | Open Access
Abdullah Al Shafi Majumder1*, Md Taufiqur Rahman1, AKM Monowarul Islam1, Mohammad Ullah1, Md Alimur Reza2, Abu Zahid Bosunia1, Ashraf Uddin Chowdhury1, Dipankar Chandra Nag1, Gobinda Kanti Paul1, Md. Abul Khair1, Md. Khalequzzaman1, Md. Mahbubur Rahman1, Md. Saiful Islam1, Md. Sk. Mamun1, Md. Zakir Hossain1, Md. Zillur Rahman1, Moeen Uddin Ahmed1, Nisith Kumar Majumder1, Nur Alam1, Rashid Ahmed1, Shahana Zaman1, Shahriar Kabir1, Shishir Kumar Basak1, SM Quamrul Huq1, Solaiman Hossain1, Sufia Jannat1, Syed Nasir Uddin1 and Zahiruddin Mahmud Ilias1
1Member of Cardiology Study Group
2Department of Medical Affairs, Beximco Pharmaceuticals Ltd, Bangladesh
*Correspondance to: Abdullah Al Shafi Majumder
Fulltext PDFBackground: Dyslipidemia is a major cause of disease burden in both the developed and developing world as a risk factor for ischemic heart disease and stroke. The effectiveness of rosuvastatin in Bangladesh has not been adequately studied. Therefore, this study was conducted to understand the efficacy and safety of rosuvastatin in real-world practice in Bangladesh.
Methods: This was a single-arm; non-intervention, multi-center, real-world study conducted in clinical practice settings in Bangladesh. Adult patients with dyslipidemia diagnosed by the treating physician and prescribed rosuvastatin (5 mg, 10 mg or 20 mg) were enrolled. The patients were treated over a 12 week period, with the primary objectives of assessing the percentage change from baseline in serum lipid profile, and assessing the proportion of patients reaching the Low-Density Lipoprotein Cholesterol (LDL-C) target goal of <100 mg/dL after 12 weeks of therapy.
Results: 280 patients were enrolled, with mean age 51.56 years, mean Body Mass Index (BMI) 26.43 kg/m2, mean baseline LDL-C 155.35 mg/dL. Mean Total Cholesterol (TC), LDL-C and Triglyceride (TG) levels decreased significantly. Overall, the mean LDL-C levels declined by 32.1% (49.9 mg/dL) from baseline to end-of-study, while the mean TC levels declined by 24.8% (58.8 mg/dL) and the mean HDL-C level increased by 16.71% (5.7 mg/dL). The proportion of patients that attained the LDL-C goal (LDL-C <100 mg/dL) in 5 mg, 10 mg and 20 mg dosage group was 24%, 49.21% and 65.71% respectively. On logistic regression analysis, higher BMI and use of clopidogrel reduced the odds of attaining LDL-C goal. Overall, 10.4% of all patients reported an Adverse Event (AE) at the end of the study. Most AEs were reported in the ‘muscle’ (6.5%) and ‘GI’ categories (6.8%).
Conclusion: This study demonstrates that all dosage form of rosuvastatin was effective in lowering TG and raising HDL-C in addition to lowering its primary target LDL-C in real-world conditions in Bangladesh. High dosage of rosuvastatin has no significant safety risk in Bangladeshi patients.
Rosuvastatin; Dyslipidemia; Cardiovascular disease
Al Shafi Majumder A, Rahman T, Monowarul Islam AKM, Ullah M, Reza A. Efficacy and Safety of Different Dosage of Rosuvastatin in Bangladeshi Patients: A Multi-Center Real-World Study. Ann Cardiol Cardiovasc Med. 2020;4(1):1036..